茶山 弘美HIROMI CHAYAMA

Last Updated :2024/04/03

所属・職名
大学院医系科学研究科（医）　准教授
メールアドレス
habehiroshima-u.ac.jp
自己紹介
私は、肝炎ウイルスのライフサイクル、肝炎ウイルスに対する宿主の免疫反応に興味を持って研究を行っています。肝炎ウイルスの細胞内での動態や免疫反応を明らかにし、肝炎ウイルスを完全に感染細胞から排除できるような新規治療薬を開発することが私の研究のゴールです。

基本情報

学位

  • 博士（医学）　(広島大学)

研究分野

  • 工学 / プロセス・化学工学 / 生物機能・バイオプロセス
  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

教育活動

授業担当

  1. 2024年, 修士課程・博士課程前期, １ターム, スタートアップ生命科学コースワーク
  2. 2024年, 修士課程・博士課程前期, ３ターム, スタートアップ生命科学コースワーク
  3. 2024年, 博士課程・博士課程後期, ３ターム, アドバンスド生命科学コースワーク

研究活動

学術論文（★は代表的な論文）

  1. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227巻, 5号, pp. 686-695, 20230301
    DOIを用いた論文検索結果へのリンク
  2. A novel cDNA-uPA/SCID/Rag2(-/-)/Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system, JOURNAL OF VIRAL HEPATITIS, 30巻, 3号, pp. 262-272, 202303
    DOIを用いた論文検索結果へのリンク
  3. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA, JOURNAL OF GENERAL VIROLOGY, 103巻, 2号, 2022
    DOIを用いた論文検索結果へのリンク
  4. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84巻, 3号, pp. 391-399, 202203
    DOIを用いた論文検索結果へのリンク
  5. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17巻, 8号, pp. 1551-1561, 2012
    DOIを用いた論文検索結果へのリンク
  6. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 205巻, 2号, pp. 204-210, 2012
    DOIを用いた論文検索結果へのリンク
  7. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19巻, 2号, pp. E126-E133, 201202
    DOIを用いた論文検索結果へのリンク
  8. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56巻, 2号, pp. 555-566, 201208
    DOIを用いた論文検索結果へのリンク
  9. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47巻, 7号, pp. 834-844, 201207
    DOIを用いた論文検索結果へのリンク
  10. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7巻, 10号, 2012
    DOIを用いた論文検索結果へのリンク
  11. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C, JOURNAL OF GENERAL VIROLOGY, 94巻, pp. 81-89, 201301
    DOIを用いた論文検索結果へのリンク
  12. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85巻, 5号, pp. 789-798, 201301
    DOIを用いた論文検索結果へのリンク
  13. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, JOURNAL OF HEPATOLOGY, 58巻, 5号, pp. 875-882, 201305
    DOIを用いた論文検索結果へのリンク
  14. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62巻, 7号, pp. 1055-1061, 201307
    DOIを用いた論文検索結果へのリンク
  15. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108巻, 9号, pp. 1464-1472, 201309
    DOIを用いた論文検索結果へのリンク
  16. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48巻, 10号, pp. 1188-1204, 201310
    DOIを用いた論文検索結果へのリンク
  17. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441巻, 1号, pp. 230-235, 2013
    DOIを用いた論文検索結果へのリンク
  18. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN- expression and inducing IL-22, INTERNATIONAL IMMUNOLOGY, 26巻, 3号, pp. 129-137, 201405
    DOIを用いた論文検索結果へのリンク
  19. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir., J Hepatol., 58巻, pp. 646-654, 20130501
  20. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., J Infect Dis., 204巻, pp. 224-228, 20110401
  21. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PLoS One., 6巻, pp. e23856, 20110801
  22. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., J Hepatol., 54巻, pp. 872-878, 20110501
  23. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations., J Gen Virol., 92巻, pp. 1071-1081, 20110801
  24. ★, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers., Nat Genet., 43巻, pp. 797-800, 20111001
  25. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population., Hum Mol Genet., 20巻, pp. 3884-3892, 20110301
  26. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol., 54巻, pp. 408-414, 20110901
  27. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology., 54巻, pp. 781-788, 20110901
  28. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology., 54巻, pp. 764-771, 20110201
  29. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut., 60巻, pp. 261-267, 20110101
  30. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol., 83巻, pp. 981-988, 20110401
  31. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients., J Hepatol., 54巻, pp. 629-639, 20110101
  32. Animal model for study of human hepatitis viruses., J Gastroenterol Hepatol., 26巻, pp. 13-18, 20110701
  33. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C., J Infect Dis., 204巻, pp. 84-93, 20110601
  34. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol., 83巻, pp. 1048-1057, 20110701
  35. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., J Hepatol., 55巻, pp. 41596, 20110901
  36. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state., J Med Virol., 83巻, pp. 1597-1607, 20110601
  37. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy., J Hepatol., 54巻, pp. 1094-1101, 20110501
  38. G to A hypermutation of TT virus., Virus Res., 149巻, pp. 211-216, 20100701
  39. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., J Gen Virol., 91巻, pp. 1854-1864, 20101001
  40. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology., 139巻, pp. 1190-1197, 20100801
  41. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 54巻, pp. 3205-3211, 20100401
  42. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antivir Ther., 15巻, pp. 1087-1097, 20100401
  43. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B., Antivir Ther., 15巻, pp. 177-184, 20100901
  44. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients., J Hepatol., 53巻, pp. 439-443, 20100501
  45. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C., Gastroenterology., 136巻, pp. 1796-1805, 20090601
  46. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., J Infect Dis., 199巻, pp. 1599-1607, 20091201
  47. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., J Hepatol., 51巻, pp. 1046-1054, 20091201
  48. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection., Hepatol Res., 39巻, pp. 1159-1168, 20090901
  49. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., J Gen Virol., 89巻, pp. 2108-2113, 20080101
  50. Successful treatment of an entecavir-resistant hepatitis B virus variant., J Med Virol., 79巻, pp. 1811-1817, 20070201
  51. Dual effect of APOBEC3G on Hepatitis B virus., J Gen Virol., 88巻, pp. 432-440, 20070501
  52. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS Lett., 581巻, pp. 1983-1987, 20070501
  53. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology., 45巻, pp. 1179-1186, 20071101
  54. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrob Agents Chemother., 50巻, pp. 3867-3874, 20061201
  55. Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin, Antimicrob Agents Chemother, 20140101
  56. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLoS One, 8巻, 12号, pp. e84226, 20131201
  57. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 20131201
  58. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15巻, 2号, pp. 177-184, 2010
    DOIを用いた論文検索結果へのリンク
  59. G to A hypermutation of TT virus, VIRUS RESEARCH, 149巻, 2号, pp. 211-216, 201005
    DOIを用いた論文検索結果へのリンク
  60. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91巻, pp. 1854-1864, 201007
    DOIを用いた論文検索結果へのリンク
  61. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54巻, 5号, pp. 872-878, 201105
    DOIを用いた論文検索結果へのリンク
  62. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54巻, 8号, pp. 3205-3211, 201008
    DOIを用いた論文検索結果へのリンク
  63. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53巻, 3号, pp. 439-443, 201009
    DOIを用いた論文検索結果へのリンク
  64. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15巻, 8号, pp. 1087-1097, 2010
    DOIを用いた論文検索結果へのリンク
  65. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54巻, 3号, pp. 408-414, 201103
    DOIを用いた論文検索結果へのリンク
  66. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients, JOURNAL OF HEPATOLOGY, 54巻, 4号, pp. 629-639, 201104
    DOIを用いた論文検索結果へのリンク
  67. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54巻, 3号, pp. 781-788, 201109
    DOIを用いた論文検索結果へのリンク
  68. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 981-988, 201106
    DOIを用いた論文検索結果へのリンク
  69. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 1048-1057, 201106
    DOIを用いた論文検索結果へのリンク
  70. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92巻, pp. 1071-1081, 201105
    DOIを用いた論文検索結果へのリンク
  71. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54巻, 6号, pp. 1094-1101, 201106
    DOIを用いた論文検索結果へのリンク
  72. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55巻, 1号, pp. 11-18, 201107
    DOIを用いた論文検索結果へのリンク
  73. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204巻, 1号, pp. 84-93, 2011
    DOIを用いた論文検索結果へのリンク
  74. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83巻, 9号, pp. 1597-1607, 201109
    DOIを用いた論文検索結果へのリンク
  75. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43巻, 8号, pp. 797-U108, 201108
    DOIを用いた論文検索結果へのリンク
  76. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6巻, 8号, 2011
    DOIを用いた論文検索結果へのリンク
  77. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54巻, 3号, pp. 764-771, 201109
    DOIを用いた論文検索結果へのリンク
  78. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population, HUMAN MOLECULAR GENETICS, 20巻, 19号, pp. 3884-3892, 2011
    DOIを用いた論文検索結果へのリンク
  79. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice, NEUROCHEMISTRY INTERNATIONAL, 60巻, 8号, pp. 817-826, 201206
    DOIを用いた論文検索結果へのリンク
  80. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58巻, 4号, pp. 2105-2112, 201404
    DOIを用いた論文検索結果へのリンク
  81. Aryl hydrocarbon receptor protects against bacterial infection by promoting macrophage survival and reactive oxygen species production, INTERNATIONAL IMMUNOLOGY, 26巻, 4号, pp. 209-220, 201404
    DOIを用いた論文検索結果へのリンク
  82. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21巻, 9号, pp. E89-E97, 201409
    DOIを用いた論文検索結果へのリンク
  83. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95巻, pp. 1297-1306, 201406
    DOIを用いた論文検索結果へのリンク
  84. New Insight Into the Enhanced Effect of Pegylated Interferon-alpha, HEPATOLOGY, 60巻, 4号, pp. 1435-1437, 201410
    DOIを用いた論文検索結果へのリンク
  85. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, 201412
    DOIを用いた論文検索結果へのリンク
  86. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70巻, 3号, pp. 273-287, 201503
    DOIを用いた論文検索結果へのリンク
  87. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 3号, pp. 619-627, 201503
    DOIを用いた論文検索結果へのリンク
  88. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 158-165, 201502
    DOIを用いた論文検索結果へのリンク
  89. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 166-174, 201502
    DOIを用いた論文検索結果へのリンク
  90. Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice, AMERICAN JOURNAL OF PATHOLOGY, 185巻, 5号, pp. 1275-1285, 201505
    DOIを用いた論文検索結果へのリンク
  91. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10巻, 6号, 2015
    DOIを用いた論文検索結果へのリンク
  92. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20巻, 4号, pp. 369-375, 2015
    DOIを用いた論文検索結果へのリンク
  93. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63巻, 3号, pp. 554-563, 201509
    DOIを用いた論文検索結果へのリンク
  94. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72巻, 1号, pp. 91-102, 201601
    DOIを用いた論文検索結果へのリンク
  95. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213巻, pp. 62-68, 2016
    DOIを用いた論文検索結果へのリンク
  96. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51巻, 11号, pp. 1073-1080, 201611
    DOIを用いた論文検索結果へのリンク
  97. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus, GENES TO CELLS, 21巻, 11号, pp. 1253-1262, 201611
    DOIを用いた論文検索結果へのリンク
  98. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21巻, 4号, pp. 307-315, 2016
    DOIを用いた論文検索結果へのリンク
  99. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214巻, 11号, pp. 1687-1694, 2016
    DOIを用いた論文検索結果へのリンク
  100. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12巻, 3号, 2017
    DOIを用いた論文検索結果へのリンク
  101. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 6号, 201706
    DOIを用いた論文検索結果へのリンク
  102. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98巻, 5号, pp. 1040-1047, 201705
    DOIを用いた論文検索結果へのリンク
  103. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, 201801
    DOIを用いた論文検索結果へのリンク
  104. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp. 269-280, 201802
    DOIを用いた論文検索結果へのリンク
  105. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 9号, 201709
    DOIを用いた論文検索結果へのリンク
  106. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500巻, 2号, pp. 152-157, 2018
    DOIを用いた論文検索結果へのリンク
  107. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99巻, 8号, pp. 1058-1065, 201808
    DOIを用いた論文検索結果へのリンク
  108. Effects of sesamin and capsaicin on the mRNA expressions of delta6 and delta5 desaturases in rat primary cultured hepatocytes., Journal of nutritional science and vitaminology, 49巻, 6号, 2003
  109. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrobial agents and chemotherapy, 50巻, 11号, 2006
  110. Dual effect of APOBEC3G on Hepatitis B virus., The Journal of general virology, 88巻, Pt 2号, 2007
  111. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology (Baltimore, Md.), 45巻, 5号, 2007
  112. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS letters, 581巻, 10号, 2007
  113. Successful treatment of an entecavir-resistant hepatitis B virus variant., Journal of medical virology, 79巻, 12号, 2007
  114. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., The Journal of general virology, 89巻, Pt 9号, 2008
  115. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., The Journal of infectious diseases, 199巻, 11号, 2009
  116. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., Journal of hepatology, 51巻, 6号, 2009
  117. G to A hypermutation of TT virus., Virus research, 149巻, 2号, 2010
  118. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., The Journal of general virology, 91巻, Pt 7号, 2010
  119. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrobial agents and chemotherapy, 54巻, 8号, 2010
  120. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., Journal of hepatology, 54巻, 5号, 2011
  121. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., Journal of hepatology, 55巻, 1号, 2011
  122. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antiviral therapy, 15巻, 8号, 2010
  123. Animal model for study of human hepatitis viruses., Journal of gastroenterology and hepatology, 26巻, 1号, 2011
  124. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., Journal of medical virology, 83巻, 6号, 2011
  125. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  126. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  127. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., The Journal of infectious diseases, 204巻, 2号, 2011
  128. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PloS one, 6巻, 8号, 2011
  129. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse., Hepatology (Baltimore, Md.), 56巻, 2号, 2012
  130. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients., Journal of gastroenterology, 47巻, 7号, 2012
  131. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice., Neurochemistry international, 60巻, 8号, 2012
  132. Identification of novel HCV deletion mutants in chronic hepatitis C patients., Antiviral therapy, 17巻, 8号, 2012
  133. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle., PloS one, 7巻, 10号, 2012
  134. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice., Gut, 62巻, 7号, 2013
  135. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients., Journal of gastroenterology, 48巻, 10号, 2013
  136. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B., Journal of medical virology, 85巻, 5号, 2013
  137. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing., The American journal of gastroenterology, 108巻, 9号, 2013
  138. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections., Biochemical and biophysical research communications, 441巻, 1号, 2013
  139. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., Journal of gastroenterology, 49巻, 12号, 2014
  140. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study., PloS one, 8巻, 12号, 2013
  141. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin., Antimicrobial agents and chemotherapy, 58巻, 4号, 2014
  142. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population., The Journal of general virology, 95巻, Pt 6号, 2014
  143. New insight into the enhanced effect of pegylated interferon-α., Hepatology (Baltimore, Md.), 60巻, 4号, 2014
  144. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway., Journal of gastroenterology and hepatology, 30巻, 3号, 2015
  145. Differences in serum microRNA profiles in hepatitis B and C virus infection., The Journal of infection, 70巻, 3号, 2015
  146. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice., The American journal of pathology, 185巻, 5号, 2015
  147. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A., Journal of hepatology, 63巻, 3号, 2015
  148. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy., Journal of medical virology, 87巻, 11号, 2015
  149. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay., PloS one, 10巻, 6号, 2015
  150. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice., Journal of virology, 89巻, 19号, 2015
  151. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones., The Journal of infection, 72巻, 1号, 2016
  152. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice., Antiviral therapy, 21巻, 4号, 2016
  153. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice., Virus research, 213巻, 2016
  154. Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders., The international journal of neuropsychopharmacology, 19巻, 9号, 2016
  155. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection., Journal of gastroenterology, 51巻, 11号, 2016
  156. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates., Hepatology (Baltimore, Md.), 64巻, 4号, 2016
  157. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing., The Journal of infectious diseases, 214巻, 11号, 2016
  158. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology., The Journal of general virology, 98巻, 5号, 2017
  159. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy., Cellular and molecular gastroenterology and hepatology, 1巻, 5号, 2015
  160. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus., PloS one, 12巻, 3号, 2017
  161. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus., Antimicrobial agents and chemotherapy, 61巻, 6号, 2017
  162. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  163. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  164. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice., Antimicrobial agents and chemotherapy, 61巻, 9号, 2017
  165. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease., Journal of gastroenterology, 53巻, 2号, 2018
  166. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antiviral therapy, 23巻, 3号, 2018
  167. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice., Biochemical and biophysical research communications, 500巻, 2号, 2018
  168. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study., Antiviral therapy, 2018
  169. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure., The Journal of general virology, 99巻, 8号, 2018
  170. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients., Journal of viral hepatitis, 2018
  171. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25巻, 12号, pp. 1555-1564, 201812
    DOIを用いた論文検索結果へのリンク
  172. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525巻, pp. 48-61, 201812
    DOIを用いた論文検索結果へのリンク
  173. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23巻, 3号, pp. 239-248, 2018
    DOIを用いた論文検索結果へのリンク
  174. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23巻, 8号, pp. 639-646, 2018
    DOIを用いた論文検索結果へのリンク
  175. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9巻, 20190611
    DOIを用いた論文検索結果へのリンク
  176. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
    DOIを用いた論文検索結果へのリンク
  177. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
    DOIを用いた論文検索結果へのリンク
  178. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92巻, pp. 210-218, 202002
  179. Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs., Microbiol Immunol., 64巻, 4号, pp. 296-303, 202004
  180. Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1., J Infect Dis., 2020
  181. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib., Ther Adv Med Oncol.

招待講演、口頭・ポスター発表等

  1. 2023年06月21日, 通常, 英語
  2. HBV特異的幹細胞様メモリーT細胞(Tscm)の検出と機能解析, 第69回日本ウイルス学会学術集会, 2022年11月13日, 通常, 英語, 日本ウイルス学会, 長崎
  3. 2021年11月12日, 通常, 英語
  4. 2018年10月27日, 通常, 英語
  5. 2016年11月11日, 通常, 英語
  6. 2015年11月13日, 通常, 英語

外部資金

競争的資金等の採択状況

  1. 科学研究費助成事業(基盤研究(C)), B型肝炎ウイルス持続感染の完治を目指すHBV特異的Tscmを用いた新規治療の探索, 2022年, 2025年
  2. 民間からの助成金, IL28B 遺伝子多型の生物学的効果の機序解明に関する研究, 2011年
  3. 科学研究費助成事業(基盤研究(C)), ヒト肝細胞キメラマウスとバキュロウイルスを用いた遺伝病モデルの創生, 2014年, 2016年
    関連URL
  4. 科学研究費助成事業(若手研究(B)), ヒト肝細胞キメラマウスと次世代シーケンサーを用いた肝炎ウイルスゲノムの解析, 2012年, 2013年
    関連URL
  5. 科学研究費助成事業(若手研究(B)), IL-28BのSNPとHCV遺伝子に関する研究, 2010年, 2011年
    関連URL
  6. 平成30年度地球規模保健課題解決推進のための研究事業, 2018年, 2019年